IPO - Profile


Health Care > Medical Electronics



We are a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, or OSA. Our lead solution is the Genio system, a CE-Marked, patient-centric, minimally invasive, next generation hypoglossal neurostimulation therapy for the treatment of moderate to severe OSA.

OSA is the world’s most common sleep disordered breathing condition and is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke. Our innovative technology platform is a first-of-its-kind hypoglossal nerve stimulation device designed to treat OSA through bilateral stimulation, by More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$30.00 2,800,000 Positive High 6.35%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors

Deal Highlights

Deal Tracker

IPO Dates

Filing 29 Jun, 2021

Offer 02 Jul, 2021

Look Ahead

Lock Up Expiry Jan 02, 2022

IPO Terms

Offer Price $30.00
Offer Size 2M

Market Sentiments

Stock Price